S&P 500   3,362.09 (-0.71%)
DOW   29,147.14 (-0.68%)
QQQ   233.65 (-1.41%)
FB   214.65 (-1.31%)
MSFT   183.28 (-2.14%)
GOOGL   1,509.48 (-1.01%)
AMZN   2,143.71 (-1.22%)
NVDA   306.56 (-2.59%)
BABA   217.11 (-2.26%)
MU   58.60 (-2.33%)
GE   12.51 (-0.79%)
TSLA   886.74 (-3.34%)
AMD   57.18 (-2.92%)
T   38.51 (+0.18%)
PRI   136.10 (+0.30%)
BAC   34.79 (+0.20%)
DIS   139.39 (-1.35%)
GILD   66.47 (-1.31%)
S&P 500   3,362.09 (-0.71%)
DOW   29,147.14 (-0.68%)
QQQ   233.65 (-1.41%)
FB   214.65 (-1.31%)
MSFT   183.28 (-2.14%)
GOOGL   1,509.48 (-1.01%)
AMZN   2,143.71 (-1.22%)
NVDA   306.56 (-2.59%)
BABA   217.11 (-2.26%)
MU   58.60 (-2.33%)
GE   12.51 (-0.79%)
TSLA   886.74 (-3.34%)
AMD   57.18 (-2.92%)
T   38.51 (+0.18%)
PRI   136.10 (+0.30%)
BAC   34.79 (+0.20%)
DIS   139.39 (-1.35%)
GILD   66.47 (-1.31%)
S&P 500   3,362.09 (-0.71%)
DOW   29,147.14 (-0.68%)
QQQ   233.65 (-1.41%)
FB   214.65 (-1.31%)
MSFT   183.28 (-2.14%)
GOOGL   1,509.48 (-1.01%)
AMZN   2,143.71 (-1.22%)
NVDA   306.56 (-2.59%)
BABA   217.11 (-2.26%)
MU   58.60 (-2.33%)
GE   12.51 (-0.79%)
TSLA   886.74 (-3.34%)
AMD   57.18 (-2.92%)
T   38.51 (+0.18%)
PRI   136.10 (+0.30%)
BAC   34.79 (+0.20%)
DIS   139.39 (-1.35%)
GILD   66.47 (-1.31%)
S&P 500   3,362.09 (-0.71%)
DOW   29,147.14 (-0.68%)
QQQ   233.65 (-1.41%)
FB   214.65 (-1.31%)
MSFT   183.28 (-2.14%)
GOOGL   1,509.48 (-1.01%)
AMZN   2,143.71 (-1.22%)
NVDA   306.56 (-2.59%)
BABA   217.11 (-2.26%)
MU   58.60 (-2.33%)
GE   12.51 (-0.79%)
TSLA   886.74 (-3.34%)
AMD   57.18 (-2.92%)
T   38.51 (+0.18%)
PRI   136.10 (+0.30%)
BAC   34.79 (+0.20%)
DIS   139.39 (-1.35%)
GILD   66.47 (-1.31%)
Log in

NASDAQ:AVDL - Avadel Pharmaceuticals Stock Price, Forecast & News

$7.08
-0.06 (-0.84 %)
(As of 02/20/2020 01:16 PM ET)
Today's Range
$7.08
Now: $7.08
$7.30
50-Day Range
$6.42
MA: $7.18
$8.25
52-Week Range
$1.03
Now: $7.08
$8.49
Volume2,531 shs
Average Volume565,301 shs
Market Capitalization$265.15 million
P/E RatioN/A
Dividend YieldN/A
Beta1.82
Avadel Pharmaceuticals plc operates as a specialty pharmaceutical company in the United States, France, and Ireland. The company primarily develops FT218, which is in a Phase 3 clinical trial for the treatment of narcolepsy patients suffering from excessive daytime sleepiness (EDS) and cataplexy. It also markets three sterile injectable drugs used in the hospital setting, including Akovaz that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia; Bloxiverz, a cholinesterase inhibitor indicated for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery; and Vazculep, a phenylephrine hydrochloride injection indicated for the treatment of clinically important hypotension. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AVDL
CUSIPN/A
Phone353-1485-1200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$103.27 million
Book Value$0.08 per share

Profitability

Net Income$-95,300,000.00
Net Margins-136.46%

Miscellaneous

Employees144
Market Cap$265.15 million
Next Earnings Date3/20/2020 (Estimated)
OptionableOptionable

Receive AVDL News and Ratings via Email

Sign-up to receive the latest news and ratings for AVDL and its competitors with MarketBeat's FREE daily newsletter.


Avadel Pharmaceuticals (NASDAQ:AVDL) Frequently Asked Questions

What is Avadel Pharmaceuticals' stock symbol?

Avadel Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVDL."

How will Avadel Pharmaceuticals' stock buyback program work?

Avadel Pharmaceuticals declared that its Board of Directors has approved a share repurchase plan on Wednesday, March 28th 2018, which permits the company to repurchase $7,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization permits the company to purchase up to 2.7% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company's board of directors believes its stock is undervalued.

How were Avadel Pharmaceuticals' earnings last quarter?

Avadel Pharmaceuticals PLC (NASDAQ:AVDL) released its earnings results on Tuesday, November, 12th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.27) by $0.03. The firm earned $14.23 million during the quarter. Avadel Pharmaceuticals had a negative net margin of 136.46% and a negative return on equity of 608.01%. View Avadel Pharmaceuticals' Earnings History.

When is Avadel Pharmaceuticals' next earnings date?

Avadel Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Friday, March 20th 2020. View Earnings Estimates for Avadel Pharmaceuticals.

What guidance has Avadel Pharmaceuticals issued on next quarter's earnings?

Avadel Pharmaceuticals updated its FY 2019 Pre-Market earnings guidance on Monday, November, 25th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $$55 million, compared to the consensus revenue estimate of $$50.99 million.

What price target have analysts set for AVDL?

3 brokers have issued 1-year price objectives for Avadel Pharmaceuticals' shares. Their forecasts range from $6.00 to $15.00. On average, they expect Avadel Pharmaceuticals' stock price to reach $9.00 in the next year. This suggests a possible upside of 27.1% from the stock's current price. View Analyst Price Targets for Avadel Pharmaceuticals.

What is the consensus analysts' recommendation for Avadel Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avadel Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Avadel Pharmaceuticals.

Has Avadel Pharmaceuticals been receiving favorable news coverage?

Media stories about AVDL stock have trended extremely negative this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Avadel Pharmaceuticals earned a news sentiment score of -4.3 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Avadel Pharmaceuticals.

Who are some of Avadel Pharmaceuticals' key competitors?

What other stocks do shareholders of Avadel Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avadel Pharmaceuticals investors own include Intelsat (I), Bank of America (BAC), Fossil Group (FOSL), Chaarat Gold (CGH), Associated British Foods (ABF), AMC Entertainment (AMC), Ciena (CIEN), Apollo Global Management (APO), First Data (FDC) and Cypress Semiconductor (CY).

Who are Avadel Pharmaceuticals' key executives?

Avadel Pharmaceuticals' management team includes the folowing people:
  • Mr. Michael F. Kanan, Sr. VP & CFO (Age 56)
  • Mr. Phillandas T. Thompson, Sr. VP, Gen. Counsel & Corp. Sec. (Age 45)
  • Mr. Gregory J. Divis, VP of Corp. and Bus. Devel. (Age 54)
  • Ms. Sandra L. Hatten, Sr. VP of Quality & Regulatory Affairs (Age 62)
  • Mr. Gregory J. Divis Jr., Interim Chief Exec. Officer (Age 52)

Who are Avadel Pharmaceuticals' major shareholders?

Avadel Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Brandes Investment Partners LP (9.75%), Broadfin Capital LLC (2.75%), Renaissance Technologies LLC (2.28%), Iridian Asset Management LLC CT (0.83%), Keel Point LLC (0.11%) and Perceptive Advisors LLC (0.02%). Company insiders that own Avadel Pharmaceuticals stock include Eric J Ende, Geoffrey Michael Glass, Greg J Divis, James E Flynn, Michael S Anderson and Sandra L Hatten. View Institutional Ownership Trends for Avadel Pharmaceuticals.

Which major investors are selling Avadel Pharmaceuticals stock?

AVDL stock was sold by a variety of institutional investors in the last quarter, including Brandes Investment Partners LP and Broadfin Capital LLC. View Insider Buying and Selling for Avadel Pharmaceuticals.

Which major investors are buying Avadel Pharmaceuticals stock?

AVDL stock was purchased by a variety of institutional investors in the last quarter, including Iridian Asset Management LLC CT, Keel Point LLC, Renaissance Technologies LLC, Perceptive Advisors LLC, Perceptive Advisors LLC, Carmichael Hill & Associates Inc., Steward Partners Investment Advisory LLC and UBS Group AG. Company insiders that have bought Avadel Pharmaceuticals stock in the last two years include Eric J Ende, Geoffrey Michael Glass, Greg J Divis and Michael S Anderson. View Insider Buying and Selling for Avadel Pharmaceuticals.

How do I buy shares of Avadel Pharmaceuticals?

Shares of AVDL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Avadel Pharmaceuticals' stock price today?

One share of AVDL stock can currently be purchased for approximately $7.08.

How big of a company is Avadel Pharmaceuticals?

Avadel Pharmaceuticals has a market capitalization of $265.15 million and generates $103.27 million in revenue each year. The company earns $-95,300,000.00 in net income (profit) each year or ($1.99) on an earnings per share basis. Avadel Pharmaceuticals employs 144 workers across the globe.View Additional Information About Avadel Pharmaceuticals.

What is Avadel Pharmaceuticals' official website?

The official website for Avadel Pharmaceuticals is http://www.avadel.com/.

How can I contact Avadel Pharmaceuticals?

Avadel Pharmaceuticals' mailing address is BLOCK 10-1 BLANCHARDSTOWN CORPORATE PARK BALLYCOOLIN, DUBLIN L2, 63005. The company can be reached via phone at 353-1485-1200 or via email at [email protected]


MarketBeat Community Rating for Avadel Pharmaceuticals (NASDAQ AVDL)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  267 (Vote Outperform)
Underperform Votes:  271 (Vote Underperform)
Total Votes:  538
MarketBeat's community ratings are surveys of what our community members think about Avadel Pharmaceuticals and other stocks. Vote "Outperform" if you believe AVDL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AVDL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/20/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel